Aeglea BioTherapeutics Investor Presentation Deck

SPY001 is designed to be a long-acting anti-a437 SPYRE IDENTICAL EPITOPE TARGET AS VEDOLIZUMAB COMPARABLE POTENCY AND SELECTIVITY AS VEDOLIZUMAB SUB-CUTANEOUS, EXTENDED HALF-LIFE mAb PREDICTED TO ENABLE Q8-12W DOSING TAI 9

View entire presentation